Loading...
ESMO Lung Cancer Congress_older2025-01-28T17:03:13+01:00

ESMO 2019 – Barcelona

Lecture Board: Maximilian Hochmair, MD; Stephen Liu, MD; Michaël Duruisseaux, MD, PhD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ESMO – Lung Cancer – 2019

ESMO 2019 Lung Cancer English

Full report (english)

ESMO 2019 Lung Cancer Mandarin

Full report (mandarin)

ESMO 2019 Lung Cancer Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ESMO 2019

Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.

Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.

Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.

Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.

Immunotherapy improves outcomes when administered together with other therapies such as cytotoxic agents, but also appears to combine well with antiangiogenic drugs based on synergy at the tumor microenvironment level. These insights might fuel new therapeutic algorithms, particularly in patients without driver mutations.

Michaël Duruisseaux • MD • PhD, Respiratory Department, Hôpital Louis Pradel Hospices Civiles de Lyon Cancer Institute Lyon, France

ESMO 2018 – Munich

Lecture Board: Maximilian Hochmair, MD; Enriqueta Felip, MD, PhD; Sanjay Popat, PhD, FRCP
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ESMO 2018

ESMO 2018 English

Full report (english)

ESMO 2018 Mandarin

Full report (mandarin)

ESMO 2018 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ESMO 2018

Sanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.

Luis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.

Approximately 25,000 participants including experts from various oncology disciplines, healthcare policy makers, and patient advocates convened from all over the world to discuss innovations and the major challenge of turning new insights into actual improvements in cancer patient care. Various obstacles of structural and financial nature still tend to impede this process in many countries, and joint efforts need to be put into the task of overcoming them.

Sanjay Popat • PhD • FRCP, Consultant Thoracic Medical Oncologist, Royal Marsden Hospital, London, UK

ESMO 2017 – Madrid

Lecture Board: David R. Gandara, MD; Nicolas Girard, MD, PhD; Maximilian Hochmair, MD; Silvia Novello, MD, PhD; Michael Thomas, MD; Gérard Zalcman, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ESMO 2017

ESMO 2017 English

Full report (english)

ESMO 2017 Mandarin

Full report (mandarin)

ESMO 2017 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ESMO 2017

Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.

Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.

Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.

Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.

In the area of targeted therapies, the debate on sequencing of drugs is gaining momentum, as head-to-head comparisons have shown superiority of potent later-generation drugs over established first-line compounds. This is true for the EGFR tyrosine kinase inhibitor osimertinib, which outperformed gefitinib and erlotinib in EGFR-mutant lung cancer, as well as for the ALK inhibitor alectinib that gave rise to improvements in progression-free survival and central nervous system outcomes when compared to crizotinib in the ALK-positive setting.

David R. Gandara • MD, Professor of Medicine UC Davis Comprehensive Cancer Center Sacramento, California, USA

ESMO 2016 – Copenhagen

Lecture Board: Maximilian Hochmair, MD; Anders Mellemgaard, MD, PhD; Silvia Novello, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ESMO 2016

ESMO 2016 English

Full report (english)

ESMO 2016 Spanish

Full report (spanish)

ESMO 2016 Mandarin

Full report (mandarin)

EXPERT VIDEOS

All video interviews from ESMO 2016

Enriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.

Martin Reck discusses the management of immunotherapy related adverse events.

Pasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.

Anders Mellemgaard on anti-angiogenesis treatments

Of course, from a clinician’s point of view, therapeutic innovation is the more spectacular part of lung-cancer–related changes. Novel approaches address targets that are not confined to the tumour cell, which had been at the centre of treatment considerations for a long time.

Silvia Novello • MD • PhD, University of Turin, Italy
Go to Top